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Abstract
Cancer treatment has much room for improvement, as therapies today cannot
differentiate well between what cells are part of a tumor and which are healthy. Our
research involves targeting cancer cells by their overexpressed folic acid receptors, and
delivering small interfering RNAs (siRNAs) to silence genes crucial to cell survival by
the RNA interference gene knockdown pathway. By using Gaussia luciferase siRNA
(siGLuc) as a model for cell delivery, we have been able to test our ability to deliver
siRNA via a gold nanoparticle delivery system, also developed in our lab. We also
synthesized ribonucleotide reductase siRNA (siRRM2), which will become our lab’s
gene of focus in the future, as this siRNA has potential to kill cancer cells.
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Chapter 1: Introduction

Cancer is a group of diseases distinguished by uninhibited growth and division of
irregular cells. It is the second leading cause of death in the United States today, and it
has no known cure.2 While there are hundreds of treatments that may or may not help
improve a cancer patient’s lifestyle or longevity, they all have their own innate problems.
While surgery is a common method of tumor removal, it is invasive and has many
potential harmful side effects and results. Stem cell transplants are risky, as the body will
reject them sometimes. Chemotherapy and radiation therapy both cause harm to
normally functioning cells as well as cancer cells. Other therapies include hormonal
treatments and biological treatments. While sometimes one or more of these treatments
may be necessary for certain patients on a case-to-case basis, a new type of treatment is
being developed called targeted therapy. The idea is that targeted therapy will only harm
cancer cells while causing minimal damage to cells that are functioning properly.
Targeted treatment involves a few different approaches. First and foremost, there
must be a way to target cancer cells specifically. Secondly, there has to be a treatment
mechanism, or some molecule, to kill the cancer cell. Lastly, that molecule needs a
delivery system in order to get to the cancer cell. Our form of targeting is by a folic acid
molecule, our treatment mechanism is RNA interference (RNAi) with small interfering
RNAs (siRNAs), and our delivery system is a gold nanoparticle (AuNP),
polyethyleneimine (PEI), polyethylene glycol (PEG) conjugate nanoplex.
Folic acid (FA), or Vitamin B9, is crucial in maintaining many cell’s life cycles. It
is believed to be important in DNA synthesis, but is known to be in high demand among
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cells that divide rapidly, namely cancer cells. It has been shown that some types of
cancers tend to overexpress folate receptors.12 It has been shown that cells
overexpressing FA receptors intake more FA, and have the capacity to allow the intake of
molecules conjugated to FA through endocytosis. It is believed that this endocytosis is
via the caveolin receptor-mediated endocytotic pathway.6
RNA interference (RNAi) is how this nanoplex will actually do damage to cancer
cells. RNAi is an efficient regulatory method that cells use to silence genes and regulate
gene expression via small interfering RNAs (siRNAs). These siRNAs are short RNAs,
18-21 nucleotides long, that complement specific portions of certain messenger RNAs
(mRNA). An enzyme called Dicer will process siRNAs from a long double-stranded
RNA, that then in turn is loaded onto an RNA-induced silencing complex, or RISC. RISC
is a multiprotein complex that has an incorporated RNase, an enzyme that cuts RNA.
With siRNA as its guide to a specific portion of an mRNA, RISC will cut an mRNA
before it can be fully translated into protein.1 Figure 1 below illustrates this process:
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Figure 1: RNA Interference Pathway

Figure 1: The RNAi mechanism using siRNA to stop gene expression. The Dicer protein “dices” the
specific double-stranded RNA into shorter fragments. A RISC (RNA-induced silencing complex) protein
complex incorporates one strand of the dssiRNA to the mRNA that it targets, and makes cuts in the mRNA,
causing degradation. Therefore, there is no translation into the coded protein.
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So, the goal of our research is to incorporate an siRNA into our delivery vehicle that will
target an mRNA that is crucial for a cell to maintain its life cycle.
The siRNA I am using in my project is RRM2 siRNA, or the siRNA that targets
ribonucleotide reductase subunit 2. Ribonucleotide reductase is an enzyme that catalyzes
the reaction of forming deoxyribonucleotides from ribonucleotides.
Deoxyribonucleotides are important for DNA synthesis. Ribonucleotide reductase works
via a free radical reaction, allowing for the removal of the 2’ hydroxyl group from the
pentose sugar of a ribonucleotide. The siRNA I am using, which has sense and antisense
strands, is made of the following sequence:

Table 1: Human Ribonucleotide Reductase siRNA Template DNA Sequence
RRM2 Sense
DNA (5'-3')

CGTAATACGACTCACTATTAGGAGAGAGTAAGAGAAATCCGCATCT
AGATGCGGATTTCTCTTACTCTCTCCTAATAGTGAGTCGTATTACG

Antisense
(5'-3')

CGTAATACGACTCACTATTAGGAGATGCGGATTTCTCTTACTCTCTCCTTT
AAAGGAGAGAGTAAGAGAAATCCGCATCTCCTAATAGTGAGTCGTATTACG

Table 2: Human Ribonucleotide Reductase siRNA Sequence
RRM2 siRNA

Sense
(5’-3’)
Antisense
(5’-3’)

AGGAGAGAGUAAGAGAAAUCCGCAUCU

AGGAGAUGCGGAUUUCUCUUACUCUCUCCUUU

My work has involved this siRNA’s synthesis and the transfection of cells with siRRM2
bound to a gold nanoparticle drug delivery vehicle.
The main method of delivering the siRNA into the cells is by gold nanoparticles
(AuNPs). Gold nanoparticles are a good delivery platform, mainly for its
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biocompatibility, high load capacity, and lack of cytotoxicity.9 Overall, the methods of
performing chemistry with AuNPs are not complicated, AuNPs can carry many siRNA
molecules, and they show no harmful effects on cells themselves. The AuNPs were
stabilized by polyethyleneimine (PEI) and polyethylene glycol (PEG), polymers that
allow for linking of RNA and FA. A theoretical structure is shown below:

Figure 2: A Theoretical Structure of the Gold Nanoplex

Figure 2: The gold nanoplex is synthesized by layer-by-layer technology, adding each layer as a sphere
surrounding the last. My research experiments were mainly carried out with siRNA as the outer layer, as
folic acid targeting is still a goal for future work.

The nanoplex was built with layer-by-layer technology,3 where we first linked PEI to
AuNP, followed by RNA, followed by a PEI/PEG conjugate, while FA was added last.
Experiments were carried out in cultures of KB cells, a human nasopharyngeal
carcinoma cell line, which are folate-receptor positive (FR+). Into these cells was
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integrated the Gaussia luciferase gene. The Gaussia luciferase gene allows the cells to
produce Gaussia luciferase (GLuc), an enzyme that reacts with the substrate luciferin to
produce chemiluminescence, light produced as a product of this chemical reaction driven
by ATP. The most important part about the KB cells having the ability to produce GLuc,
however, is that they produce it and secrete the enzyme into the medium. This allows for
us to measure the relative amount of the gene we have knocked down by measuring the
amount of luminescence the medium can produce.
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Chapter 2: Literature Review

Cancer as the Problem:
Theoretically, as described in the American Cancer Society’s “Cancer Facts and
Figures 2012,” over half a million cancer deaths in 2012 will be caused by tobacco use,
obesity, and poor nutrition—all areas that could easily be prevented. Some forms of
cancer are caused by viruses like Hepatitis B and Human Papillomavirus. Regular
screenings can help prevent all these kinds of cancer, which account for more than half of
new cancer cases. However, still cancer remains a huge problem, and people who have it
need to be rid of it. Treatments for cancer are being vehemently searched for around the
world. It is estimated that 44.85% of men develop cancer in their lifetime, while 38.08%
of women will do so as well.2 Typically, once cancer has manifested itself, it, in a sense,
develops barriers to keep itself alive in the body. “The Hallmarks of Cancer” by Hanahan
and Weinberg (2000) illustrates the six main qualities cancer demonstrates, which are
“self-sufficiency in growth signals, insensitivity to anti-growth signals, tissue invasion
and metastasis, limitless replicative potential, sustained angiogenesis and evasion of
apoptosis.” They theorize that all cancers must maintain or acquire all six of these
abilities at some point, in some way. Depending on how cancers develop these six
qualities determine the best mode of action in treatment against that specific type of
cancer.
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Treating Cancer:
Treatments for cancer are a dime-a-dozen throughout the cancer treatment world,
and targeted delivery is becoming the hope for modern and future cancer treatments. Up
and rising targeted therapeutics use RNA interference mechanisms (RNAi) to stunt
cancer cell growth. There are three known types of RNA utilized by RNAi: small
interfering RNA (siRNA), short hairpin RNA (shRNA), and micro RNA (miRNA).
Overall, of the three types, siRNA is the best to use in practice because of its small size
(typically 21-25 nucleotides) and ability to interact with target mRNAs in the cytosol
rather than the nucleus (the nuclear envelope presents another barrier).11 The specific
type of targeted treatment our lab is dealing with uses RNAi therapeutic technologies
delivering siRNAs to gene targets. My research involves interfering with the translation
of ribonucleotide reductase subunit 2 mRNA (siRRM2).
Problems with siRNA use in cancer therapeutics include its interference with
other small RNA pathways which can be slightly cytotoxic if introduced in too high a
dose.11 Also, there are barriers present in the delivery of siRNAs into the cell. Mainly, it
is easier to deliver siRNA to all areas of the body than to specific loci, which is not
incredibly useful in cancer treatment as the goal is to target a specific cluster of tumor
cells. In addition, siRNA molecules are not stable in their single-stranded form, and must
be coupled into a double-stranded structure containing a sense and anti-sense strand.5
These molecules then, are not easily taken up into cells on their own. So, the next
research problem is finding a proper mechanism or platform to deliver siRNA molecules
specifically to the cells they need to harm.
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Delivery of Targeted Treatment:
Many delivery platforms have been utilized to transfer siRNA molecules into
cells, some with decent success. These different particles include those like carbon
nanotubes, gold nanorods, and gold nanoparticles.5 Gold nanoparticles are the most
commonly used of these transport systems and are useful for delivery of many types of
molecules, including DNA and other cancer therapeutics.9 Our laboratory utilizes the
gold nanoparticle which binds to the siRNAs through PEI and PEG copolymers and
electrostatic interactions, attaching spherically around the nanoparticle. In order to
specifically target the cancerous cells, a molecule must be added that will attach only or
mainly to cancer cells’ membranes. We designed and used a folate molecule-directed
delivery method, utlilizing folic acid as the valent structure on the nanoparticle, able to
bind as a ligand to FRs.13, 14
Folic acid is taken into rapidly dividing cells as it plays a role in cell division;
cancer cells divide more rapidly than other cells, so they take in more folic acid. If the
folic acid molecule they absorb so happens to be attached to a molecule with siRNAs that
target a crucial gene’s expression, then at least one of the goals in this project will have
been accomplished because siRNA will have successfully entered the cell’s cytosol
where it has the potential to interact with mRNA.

Delivery System – Gold Nanoparticle and the Nanoplex
The gold nanoparticle is often used as a platform for molecular delivery. The
AuNP’s used in this research project were 13-15 nm in diameter. The first layer bound to
the AuNP was the polymer PEI, after which was bound the siRNA of interest. The fourth
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layer then was a PEI-PEG copolymer to prevent degradation of the RNA from cytosolic
nucleases. The fifth layer is folic acid, the targeting molecule theorized to allow
receptor-mediated endocytosis of the entire nanoplex.6

Small Interfering RNA, RNAi, and Ribonucleotide Reductase
Small interfering RNAs are utilized by the RNA Interference pathway to regulate
gene expression. In RNA interference, an siRNA will complement a corresponding
mRNA and stop its translation. The siRNA is usually 21-25 nucleotides long and is
double-stranded. The two strands, sense and antisense, have 3’ overhangs. Long
stretches of RNAs are cut into these siRNAs by the Dicer enzyme. The antisense strand
will associate with the RNA interference silencing complex (RISC), and will complement
the mRNA to guide the RISC’s site-specific mRNA cleaving. In theory, for any known
mRNA sequence, an siRNA could be synthesized and utilized by the RNAi pathway to
knockdown a specific gene. For us, ribonucleotide reductase mRNA is the target of
choice, as the enzyme ribonucleotide reductase is crucial for the synthesis of
deoxyribonucleotides from ribonucleotides. Deoxyribonucleotides are essential in DNA
synthesis. Therefore, the prevention of the formation of the ribonucleotide reductase
enzyme would prevent a cell from synthesizing DNA, causing eventual apoptosis.

Folate Receptor as the Target
Folate receptors are overexpressed in cancer cells.12 This indicates a need for
folic acid by cancer cells. It is thought that folic acid is important in cell division
processes, ones that cancer cells undergo much more often than a normal cell. By using
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folic acid in our gold nanoplex, we can potentially target these numerous folate receptors
and cause receptor-mediated endocytosis of both the folic acid and the entire attached
particle containing our protected siRNAs. Certain chemotherapies have also been
designed to target folate receptors. One drug even killed 80% of a tumor cell population
in one experiment.10
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Chapter 3: Research Methods

This study involved the design of a gold nanoparticle based siRNA delivery
system able to target the overexpressed folate receptors in cancer cells. The final siRNA
and gene target of interest was siRRM2, the siRNA that targets the 2 subunit of
ribonucleotide reductase. In this project, we sought to maximize efficiency of delivery of
the nanoparticle to the cells, as well as the knockdown efficiency once delivered, while
maintaining the lowest cellular toxicity possible.

Delivery Efficiency and the AuNP: Preliminary Studies Necessary for My Project
Much work has been done with the gold nanoparticle and its ability to be
endocytosed into cancer cells. Experimentation involved using tRNA as a model while
testing the proper amounts of PEI, RNA, PEI-PEG, and FA to add while maintaining
proper surface charge and size of the nanoparticle. Surface charge and size of the
nanoparticle were measured using Zeta Potential and Dynamic Light Scattering,
respectfully.

Cell Culture and Transfection
Cell culture involved the use of FR+ KB Cells, a folate receptor positive human
nasopharyngeal carcinoma cell line. These cells were maintained in a folate free RPMI
1680 (GIBCO) medium supplemented with 10% fetal bovine serum (FBS) (Hyclone)
with 100 units/mL penicillin and 100 μg/mL streptomycin (Millipore) at 37°C, 5% CO2
humidified air. Antibiotic additions will be referred to as “serum.”
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Cells were transfected with siRNA using 0.4 μL/100 μL DharmaFECT Duo
transfection reagent (Dharmacon). We counted cells via haemocytometer and plated
specific numbers of cells into welled plates. Controls were only given fresh media while
experimental wells were treated with DharmaFECT and siRNA or an AuPEI/siRNA
complex.

Gene Knockdown Efficiency: siGLuc Testing
In order to test the delivery efficiency of our nanoparticle before synthesizing
expensive siRRM2, we used siRNA against Gaussia luciferase as a luminescent model to
test the relative gene knockdown ability once delivered into KB cells that had had
Gaussia luciferase gene incorporated into their genome. These KB cells are also folate
receptor positive, and important characteristic for other experiments performed.
siGLuc is able to target the mRNA corresponding with Gaussia luciferase, an
enzyme capable of luminescence upon reacting with a corresponding substrate. We used
the GLuc Assay Kit including rabbit anti-GLuc (coelenterazine) (New England BioLabs)
and BioLux GLuc Assay Bufer #B3301A (New England BioLabs). Cells were treated
with AuPEI/siGLuc complex and DharmaFECT transfection reagent. DharmaFECT was
used as the control treatment as well. After 24, 48, and sometimes 72 hours, the cell
medium was removed and analyzed by Gaussia Luciferase Assay Kit. The relative
fluorescence against non-siGLuc-treated control cells was measured by Gen5
Luminometer. Results showed percentage of cells without knockdown compared to
untreated cells, giving us an idea of how efficient our nanoplex is.
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Synthesis and Preparation of siRRM2
We used the in vitro transcription (IVT) technique to synthesize our siRRM2.
This method requires the use of T7 RNA Polymerase, a fast enzyme with a low error rate
capable of polymerizing RNA from a DNA template with a specific promoter.
The procedure and materials are available in the Ampliscribe T7-Flash Transcription Kit
ASF3507 (Epicentre).
The reaction kit and procedure involved 1X Buffer, 10 mM DTT, 9 μM
nucleotide triphosphates (NTPs), 0.4 μM DNA, 1 μL T7 Polymerase per 10 μL of
reaction. The T7 Polymerase was kept on ice at all times. After adding the samples in the
addition order described, they were incubated in 37°C for 2-4 hours. To perform the
ethanol precipitation; I added 70 μL water and 10 μL 3 M NaAc to the 20 μL of mixture,
300 μL of EtOH. This was left to precipitate overnight. The solution was then
centrifuged for 8 minutes on high speed, then the supernatant was removed. The pellet
was resuspended in 20 μL of RNase-free water, then we began the purification process.
We annealed our strands after purification by adding them together in a 1:1 ratio,
followed by heating and incubation at room temperature for 30 minutes. To analyze our
annealing process, we ran a sample on a PAGE gel for 30 minutes, then used a BIORAD
Molecular Imager FX to ensure there was only one band present.

RNA Purification
We added 20 μL of dye (2XBB and XC) to each sample. We loaded 20 μL
samples onto the pre run PAGE gel, and allowed it to run for 30 minutes. After running,
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we characterized the RNA by UV shadowing, then cut out only the RNA. The cut out gel
was crushed to the consistency of mashed potatoes to increase surface area for heating
and removal of the gel by sodium acetate and ethanol precipitation reactions.

Cell Viability Tests
We removed the medium from the cells in the 96 well plates, then washed with
100 uL of Phosphate Buffered Saline (PBS) (Hyclone) for 15 minutes. We removed the
PBS and incubated in 50 μL of 4% Paraformaldehyde (PFA) (Hyclone) solution
overnight.

RT-PCR and qPCR
To determine the percentage knockdown of the RRM2 gene by siRRM2, we used
Reverse Transcription PCR to create cDNA from the lysed cells’ mRNA, then used
Quantitative PCR to determine how much RRM2 mRNA remained by comparing a
treated sample with a control sample, as well as comparing the concentrations to relative
amounts of an abundant mRNA, β-actin.
We first transfected our annealed siRRM2 into two wells in a 24 well plate using
DharmaFECT, while leaving two duplicate controls as only treated with DharmaFECT.
We transfected 4.4 μL of DharmaFECT and 2.2 μL of 40 nM siRRM2 along with 220 μL
RPMI medium and 880 μL RPMI/FBS/Serum into the two treatment wells, and used only
DharmaFECT and RPMI + RPMI/FBS/Serum in the controls.
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RNA Extraction
The cells were incubated for 48 hours, then treated with 125 μL Trizol reagent.
The cells were mixed thoroughly by pipetting, then moved into a 1.5 mL tube. This was
allowed to sit for 10 minutes.
Phase Separation
We then added 25 μL of chloroform and gently vortexed after 10 minutes. This
allowed us to precipitate out the RNA in the top aqueous layer by centrifuging for 10
minutes at 4°C and 10,000 rpm in an Eppendorf Centrifuge 5804 R. The top aqueous
layer was transferred to a new tube while the other layers were discarded.
RNA Precipitation
Then 62.5 μL of isopropanol was added to the solution, mixed well, then allowed
to sit for 15 minutes. The solution was then centrifuged for 10 minutes at 4°C and 12,000
rpm. The RNA was observed as a small pellet in the tube. The supernatant was removed,
then 150-200 μL of 70% ethanol solution was added, then incubated at - 20°C for 30
minutes. This solution was then centrifuged for 10 minutes at 4°C and 10,000 rpm. The
supernatant was removed and the RNA pellet was dissolved in 5 μL of
diethylpyrocarbonate-treated water (DEPC water, used to treat for RNase). The RNA
concentration was then measured by Genesys 10 Bio UV Spectrometer by using 1.5 μL
of solution.
Reverse Transcription
To our remaining 3.5 μL of RNA solution, we added 8.0 μL DEPC water, 2 μL
random RNA primers, and 1 μL of 10 mM dNTPs. These were heated in the Eppendorf
Mastercycler PCR for 5 minutes on program “A7005ED.” The solution was removed
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and quickly placed on ice with all other reagents. 0.5 μL of RNase inhibitor was added,
followed by 4 μL of 5x RT Buffer and 1 μL of Reverse Transcriptase. After running the
resulting solution for 2 hours in the PCR on program “A421H,” we added 200 μL of
DEPC water and stored the solution in -20°C.
qPCR
We then, tested for our target gene, RRM2, comparing results to the gene for βactin. We created a 2 uM primer stock for RRM2 by adding 1 μL of 200 uM RRM2 (F)
primer and 1 μL of 200 uM RRM2 (R) primer to 98 μL of RNase-free water. We did the
same with β-actin primers. To create our cDNA solution, we took 22 μL of our RT-stock
and mixed with 44 μL of SYBR Green fluorescent dye (Invitrogen) and 13.2 μL RNasefree water. We then combined 18 μL of cDNA solution with 2 μL of primer solution.
We now had 8 duplicate experimental tubes for qPCR, containing control-treated
cell cDNA solution being measured for each β-actin and RRM2 concentrations, as well as
siRRM2/DharmaFECT treated cell cDNA solutions being measured for each β-actin and
RRM2 concentrations.
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Chapter 4: Results
Figure 3: Transfection of siGLuc (100 nM) by DharmaFECT and AuPEI

Figure 3: Transfection of siGLuc (100 nM) by DharmaFECT and AuPEI. This figure shows
experimental expression of KB-GLuc cell media treated with siGLuc versus control cells (black) treated
with only DharmaFECT. There was little knockdown after 24 hours and about 40% knockdown after 48
hours. DharmaFECT and AuPEI transfection showed similar results. Error bars indicate standard deviation
across a triplicate study.

Figure 4: Comparing Synthetic siGLuc vs. IVT – siGLuc and DharmaFECT vs.
Lipofectamine

Figure 4: Comparing Synthetic siGLuc vs. IVT – siGLuc and DharmaFECT vs. Lipofectamine. This
This experiment compared 100 nM synthetic (purchased) siGLuc effectiveness (blue) versus our IVTsynthesized AuPEI/siGLuc (purple). DharmaFECT transfection reagent was compared to Lipofectamine
reagent (Invitrogen), and the two showed no difference. The error bars represent standard deviation across
duplicate studies. Our siGLuc shows an apparent decrease in GLuc expression.
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Figure 5: Relative Cellular Toxicity from Figure 2’s Experiment

Figure 5: Relative Cellular Toxicity from Figure 2’s Experiment. Our IVT-synthesized AuPEI/siGLuc
complex caused cell death more frequently than did other experimental trials. This accounts for much of the
decreased siGLuc expression. The error bars represent standard deviation across duplicate studies.

Figure 6: UV-Vis Characterization of siGLuc
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Figure 6: UV-Vis Characterization of siGLuc. This figure shows the relative amount of sense and
antisense strands acquired of purified siGLuc.
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Figure 7: UV-Vis Characterization of siRRM2
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Figure 7: UV-Vis Characterization of siRRM2. This figure illustrates the relative yield of antisense and
sense strands acquired after purification of siRRM2. The sense yield was very low on this first
IVT/Purification, so more had to be synthesized in another batch.

Figure 8: RT-qPCR Amplification Plots

Figure 8: RT-qPCR Amplification Plots. RT-qPCR comparing gene expression of β-actin and
ribonucleotide reductase cDNA from mRNA transcripts. The number of cycles (x-axis) for fluorescence
to reach the threshold (set at 1000 dR) indicates the relative amount of gene expression compared with a
control. The more cycles, the less gene expression. This figure simply shows that our samples did have
cDNA expressed. This was measured by tagging a fluorescent SYBR green dye.
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Figure 9: RT-qPCR Dissociation Curve

Figure 9: RT-qPCR Dissociation Curve. The RT-qPCR dissociation curve allows us to visualize the two
types of mRNA we targeted and the temperatures at which they dissociated via fluorescence. These two
curves represent β-actin and ribonucleotide reductase cDNA. This figure only explains that we did indeed
express two different cDNAs in our experiment.

Figure 10: Percentage RRM2 Gene Expression

Figure 10: Percentage RRM2 Gene Expression. Gene expression was determined by the reciprocal of
two to the power of the difference between the cycle number of the control and the cycle number of the
cells treated with siRRM2. Results show nearly 75% gene knockdown.
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Figure 11: KB Cell Viability Test
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Figure 11: KB Cell Viability Test. Cell viability was tested at 48 hours with 20 nM siRRM2 and
DharmaFECT compared to an untreated control and a DharmaFECT only control. DharmaFECT was
noted to have some cellular toxicity on its own, but not as much as Dh/siRRM2 together. Therefore our
IVT siRRM2 has the capability to kill cancer cells. The error bars in this experiment represent standard
deviation across a triplicate study.

In the first siGLuc experiments (Figure 3), where we used synthetic siGLuc (New
Englad BioLabs) we seemed to achieve a lower gene knockdown percentage (40%) than
expected. Since the AuPEI/siGLuc conjugate and DharmaFECT/siGLuc control had
similar knockdown, we can assume the AuPEI/siGLuc at least gets inside cancer cells.
Figure 4 shows a repeat experiment after we had synthesized our own IVT –
siGLuc. This data showed better knockdown, close to 60%, showing that our IVTsiGLuc caused less GLuc expression. However, Figure 5: Relative Cell Toxicity shows
also that the cytotoxicity in our experimentation was high, meaning that perhaps the
absence of GLuc expression was a result of cell death rather than gene knockdown.
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Figure 6 shows the relative amount of sense strand to antisense siGLuc strands
acquired after RNA purification. Figure 7 shows the sense strand of siRRM2 having a
much lower purity than its antisense strand. Larger reactions were done to acquire
enough sense strand to anneal with which to treat cells.
However, as Figure 10 shows, RT-qPCR told us our knockdown efficiency was
nearly 75% with siRRM2 synthesized. Figures 8 and 9 allows us to visualize signatures
of two distinct mRNAs selected for during qPCR. This shows us we indeed do have both
β-actin and ribonucleotide reductase cDNA present. Figure 11 shows the relative
cytotoxicity of our 20 nM siRRM2. While after 48 hours there was clearly apparent
knockdown, it is not known exactly if the cells are dying from the knockdown of the gene
or the activation of other cellular pathways16.
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Chapter 5: Discussion and Conclusions

The main achievements in my research involved learning about the delivery
efficiency of our nanoparticle and the knockdown efficiency of the siRNA we can
synthesize. Using siGLuc, we were able to see a few things about both topics. Also,
using RT-qPCR, we took a step toward an actual, potentially functioning cancer
treatment by confirming our IVT-synthesized siRRM2’s gene knockdown ability.
Our RT-qPCR studies, showing 75% knockdown of the RRM2 mRNA level,
compares hand-in-hand with the studies from Heidel et. al. and their research in studying
different siRRM2 capabilities. Their gene expression after 48 hours seemed to be
equivalent if not a little less than our gene knockdown15. Their group used HeLa cells
while we used KB, which may offer some explanation. Nonetheless, our siRNA
capabilities align with other literature values for gene expression post-siRRM2 treatment.
The Heidel et. al. group also used a luminescent model similar to our GLuc assay,
except they used an RRM2/luciferase hybrid plasmid that had been incorporated into
HeLa cells to determine their knockdown efficiency and gene expression15. I believe our
method of determining gene expression is more accurate, as we measure our knockdown
ability of siRRM2 with only the direct gene produced by cancer cells, not any gene that
had been incorporated into the cells. We incorporated siGLuc and tested delivery
efficiency separately in order to have better results in the future.
Problems with our results include the low yield of sense strand siRRM2 as
described in Figure 7. This problem could arise for a number of reasons, including a lessspecific promoter region for transcription or “old” materials that may have been
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contaminated in some fashion over the years. If this issue were fixed and our sense
siRRM2 IVT were more efficient, it would be possible to produce and purify more
siRRM2 at a time, thus allowing for more experimentation and results involving the
treatment of cancer cells.
Future studies will include the inclusion of siRRM2 in the gold nanoplex and
treating KB cells again, eventually without DharmaFECT, to calculate the gene
knockdown capability of the nanoplex by using RT-qPCR. First, there are other RNA
binding considerations with the AuPEI complex that must be accomplished.
Future work may also involve the removal of the 5’ triphosphate group, a group
known to trigger other pathways that could bring about cell death, like the RIG-I
pathway16. However, it is important to note that the siRNA we synthesize in our lab can
effectively cause cell death in FR+ KB cancer cells, the first, most important step in
synthesizing the nanoplex.
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